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Abstract
Aims Left ventricular diastolic dysfunction (LVDD) is common in obese subjects, and a relationship between epicardial adi-
pose tissue (EAT), increased adipocytokines, and cardiovascular diseases has been reported. This study sought to examine
as to whether the adipo-ﬁbrokine activin A is a link between increased EAT, the metabolic syndrome (MetS), and LVDD in se-
verely obese subjects.
Methods and results In 236 obese subjects (ø body mass index 39.8 ± 7.9 kg/m2) with a variable degree of the MetS and in
60 healthy non-obese controls (ø body mass index 24.8 ± 3.4 kg/m2), serum activin A levels were measured and correlated
with parameters of the MetS, epicardial fat thickness (EFT), and echocardiographic parameters of LVDD. Activin A levels were
higher in obese than in non-obese subjects (362 ± 124 vs. 301 ± 94 pg/mL, P = 0.0004), increased with the number of MetS
components (from 285 ± 82 with no MetS component, 323 ± 94 with one or two MetS components, to 403 ± 131 pg/mL with
≥3 MetS components, P < 0.0001) and correlated with EFT (r = 0.41, P < 0.001). Furthermore, activin A levels were related to
several parameters of LVDD [e.g. left atrial size (382 ± 117 vs. 352 125 pg/mL, P = 0.024), E/e0 (394 ± 108 vs. 356 ± 127 pg/mL,
P = 0.005)]. LVDD was highest in MetS obese subjects with high EFT (44.3%) compared with MetS obese subjects with low EFT
(27.0%), non-MetS obese subjects with high EFT (24.2%), and non-MetS obese subjects with low EFT (10.6%, P < 0.0001).
Conclusions In severe obesity, activin A was signiﬁcantly related to EFT, MetS, and LVDD, implicating MetS-related alter-
ations in the secretory proﬁle of EAT in the pathogenesis of obesity-related heart disease.
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Introduction
Obesity and the metabolic syndrome (MetS) are rapidly in-
creasing disorders in western countries and are associated
with a high risk of cardiovascular morbidity and mortality
and of developing heart failure.1,2 Understanding the various
underlying pathophysiological mechanism that could lead to
heart failure in the obese state is critical. Obesity leads to sys-
temic inﬂammation and alteration of the immune system net-
work with release of speciﬁc immune cell-derived cytokines in
terms of cardiovascular dysfunction.3 Adipose tissue is di-
vided into two groups (white and brown) according to mor-
phology, physiology, and embryological origin. White
adipose tissue is further divided into visceral and subcutane-
ous tissue. Visceral adipose tissue is surrounding the internal
organs and is, in contrast to subcutaneous fat, which serves
as energy resource, metabolically active with release of dif-
ferent cytokines and plays an important role in the develop-
ment of cardiovascular diseases. The epicardial fat depot is
part of the visceral adipose tissue; it is not separated by
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fascias from the myocardium with a close and strong interac-
tion between both.4 Excessive epicardial fat is common in
obesity and has a strong relationship with visceral adiposity.5
In fact, epicardial fat is a source of adipokines and inﬂamma-
tory cytokines, and there seems to be interactions through
paracrine and vasocrine mechanisms between epicardial fat
and the myocardium, particularly in subjects with the
MetS.4,6,7
In heart failure patients, increasing expression and blood
levels of the TGF-β cytokine member activin A could be dem-
onstrated.8 Activins are expressed in various tissues where
they have been shown to regulate multiple biological pro-
cesses including regulation of apoptosis, proliferation, and
differentiation of different cell types.9 Activin A is a growth
factor with various activities and has been found in a variety
of cell types at all stages of cell and human growth.
Activin A levels have been shown to increase in myocardial
infarction,10 predict worse left ventricular (LV) remodelling
and death in ST-elevation myocardial infarction,11 and were
described as stimulating cardiac ﬁbroses through activating
cardiac ﬁbroblasts,12 whereas inhibition of activin A improves
cardiac function in mice with dilated cardiomyopathy.13
Activins are highly expressed in adipose tissue and have a
role in several steps of physiologic and pathological develop-
ment of adipose tissue, supporting the hypothesis that in-
creased activity of activin A may lead to insulin resistance
and inﬂammatory status. Moreover, in type 2 diabetes pa-
tients, activin A levels were inversely associated with myocar-
dial glucose metabolism and positively with left ventricular
mass (LVM), indicating a detrimental role in early diastolic
cardiomyopathy.14 Therefore, the activin A pathway could
represent a potential therapeutic target for obesity-
associated, cardiometabolic complications. Impaired diastolic
functioning of the left ventricle appears in large percentages
of the cardiovascular asymptomatic population with diabetes
and severe obesity15,16 and represents usually an early stage
in the progression to heart failure in these subjects.15 Thus,
the aim of our study was to examine as to whether activin
A is linked between increased epicardial adipose tissue, the
MetS, and LV diastolic function in severely obese subjects.
Methods
Study population
Subjects were participants of the ‘Regensburg Weight Loss
Study’, a prospective longitudinal study evaluating excessive
body fat for its pathogenic potential in terms of cardiometa-
bolic diseases and assessing the effects of a considerable
weight reduction on interactions in systems biology.
Obese patients intending to participate in a weight reduc-
tion programme were offered enrolment in our research
study prior to the start of the programme. Patients were eli-
gible for enrolment if they were 18–65 years old, presented
with a body mass index (BMI) ≥ 30 kg/m2 and a constant
body weight in the last 3 months, and if they gave written in-
formed consent to participate in the study. Exclusion criteria
were weight reduction ≥10% of body weight in the last
6 months, cancer, pregnancy, therapy with steroids or thy-
roid hormones, known heart disease, known diabetes
mellitus type 1 or 2, known inﬂammatory bowel, rheumatoid,
or systemic diseases, known chronic renal failure, known liver
diseases, mental disorders, or addiction to drugs or alcohol.
The participants were recruited by ﬂyers and advertisements.
The study was approved by the local ethics committee. The
investigation conforms with the principles outlined in the
Declaration of Helsinki.17
Metabolic syndrome
The MetS was deﬁned according to the National Cholesterol
Education Program–Adult Treatment Panel III guidelines if at
least three of the following criteria were fulﬁlled: central obe-
sity with a waist circumference ≥ 102 cm in men and ≥88 cm
in women, dyslipidaemia with triglyceride levels ≥ 150mg/dL,
HDL cholesterol levels < 40 mg/dL in men and <50 mg/dL in
women, blood pressure ≥ 130/85 mmHg or treatment for hy-
pertension, and fasting plasma glucose levels ≥ 110 mg/dL or
presence of diabetes mellitus type 2.18
Physical performance
Patients performed the 6 min walk test at study entry. Pa-
tients were instructed to walk from end to end in an enclosed
corridor, covering as much ground as they could during
6 min, and the distance walked was measured using an elec-
tronic metre counter.
Laboratory analysis
Serum samples were collected after a 12 h overnight fast and
immediately stored at 70°C. The samples had not been
thawed before the present measurements. Fasting glucose,
insulin, and blood lipids were determined by standard
methods in the certiﬁed clinical chemistry laboratory of the
University Hospital. Insulin resistance was estimated by ho-
meostasis model assessment index. The N-terminal pro-brain
natriuretic peptide levels were determined by a standard
chemiluminescence immunoassay (Roche Diagnostics,
Mannheim, Germany). Activin A levels were determined by
enzyme-linked immunosorbent assay (Quantikine, R&D Sys-
tems Europe, Wiesbaden-Nordenstadt, Germany) and were
performed at the Medical Clinic III, Dresden University of
Technology, Germany, by investigators that were not aware
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of patients’ characteristics and outcomes. Matrix metallopro-
teinase 9 (MMP-9) levels were determined by enzyme-linked
immunosorbent assay (Quantikine, R&D Systems Europe,
Abingdon, UK); likewise, adiponectin levels were determined
by enzyme-linked immunoassay (BioVendor GmbH, Heidel-
berg, Germany).
Echocardiography
Echocardiography was performed using a standard ultra-
sound system (Philips iE33 Philips Medical Systems, Hamburg,
Germany). The LV ejection fraction was measured based on
the modiﬁed biplane Simpson’s method. The following pa-
rameters were measured according to previous American So-
ciety of Echocardiography guidelines19: parasternal long axis
diameter and apical four-chamber area. Measurements were
done just before mitral valve opening. LVM was calculated by
the Devereux formula indexed to the body surface area. Con-
ventional transmitral ﬂow was measured with pulsed wave
Doppler. Early (E) and late atrial (A) transmitral peak ﬂow ve-
locities, their ratio (E/A), and the deceleration time (DT) of
the early transmitral ﬂow velocity were measured, and three
consecutive beats were averaged. Pulsed wave tissue Doppler
imaging was performed at the junction of the lateral mitral
annulus, and three consecutive beats were averaged. Early di-
astolic velocities (e0 lateral) were recorded. Ratios of E/e0 lat-
eral and e0/a0 were calculated. All measurements were
recorded by two expert echocardiographers. We determined
the agreement between E/e0 measurements of the two ex-
pert cardiologists by the use of the concordance correlation
coefﬁcient (CCC). The CCC combines a measure for precision
and accuracy to evaluate reproducibility and inter-rater reli-
ability.20 The CCC for 20 duplicate E/e0 measurements of
the two expert sonographers was 0.976 ± 0.014 (P < 0.0001).
Left ventricular diastolic dysfunction
Diastolic dysfunction was deﬁned as fulﬁlment of the follow-
ing criteria: (i) a preserved systolic LV function (ejection frac-
tion > 50%) and (ii) the presence of at least two of the
following criteria consistent with abnormal LV relaxation, ﬁll-
ing, diastolic distensibility, diastolic stiffness, or increased na-
triuretic peptides (N-terminal pro-brain natriuretic
peptide > 220 pg/mL): E/e0 lat. > 8, E/A ≤ 0.8 together with
a DT > 200 ms, a difference between the duration of re-
versed pulmonary vein atrial systole ﬂow (Ard) and duration
of mitral A wave ﬂow (Ad): Ard – Ad > 30 ms, LV
mass > 149 g/m2 (in men), >122 g/m2 (in women) together
with (iii) an enlarged left atrial (LA) size [LA area (4 chamber
planimetry)] > 20 cm2 or LA diameter (parasternal long axis)-
48mm, and an e0 < 10 cm/s. In contrast, subjects with a nor-
mal lateral e0 ≥ 10 cm/s together with a normal LA size were
classiﬁed as having normal LV function according to the
American Society of Echocardiography 2009 and European
Society of Cardiology 2007 consensus criteria.21,22
Epicardial adipose tissue
Epicardial fat thickness (EFT) was identiﬁed as the low echo
space between the outer wall of the myocardium and the vis-
ceral layer of the pericardium in the parasternal long axis
view. It was measured during end-systole on the free wall
of the right ventricle in a perpendicular line to the aortic an-
nulus, used as an anatomic landmark. Pericardial fat, which
does not appear hyperechoic and usually is not deformed
substantially with cardiac cycles, was not included in the mea-
surement of epicardial fat.
Statistical analysis
Statistical analyses were performed with SPSS version 18.0
software (SPSS Inc., Chicago, IL, USA). Descriptive statistics
are presented as mean ± standard deviation for continuous
data and as number and percentages for categorical data.
Student’s t-test was used for comparison of different biomet-
ric, laboratory, and MetS as well as echocardiographic param-
eters for normal distributed and independent data. Multiple
linear regression analysis was performed to account for co-
variates such as age, sex, and BMI. Skewed data were evalu-
ated by the non-parametric Wilcoxon (Mann–Whitney) test.
Correlation analyses were assessed by Pearson’s correlation
coefﬁcient. Any P-value < 0.05 was considered to be statisti-
cally signiﬁcant.
Results
Baseline characteristics
Baseline characteristics of the study population stratiﬁed by
obesity are displayed in Table 1. As expected in obese sub-
jects (ø BMI 39.8 ± 7.9 kg/m2), all components of the MetS
were signiﬁcantly different with higher systolic and diastolic
blood pressure levels, higher blood glucose levels, higher ho-
meostasis model assessment index levels, higher triglyceride
levels, and lower HDL cholesterol levels. Similarly, activin A
levels were signiﬁcantly higher in obese than in non-obese
subjects (362 ± 124 vs. 301 ± 94 pg/ml, P < 0.001).
Activin A and metabolic syndrome
The association of activin A levels to different MetS parame-
ters is displayed in Supporting Information, Table S1.
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Participants with MetS had signiﬁcantly higher activin A
levels. Speciﬁcally, obese subjects with increased waist cir-
cumference, elevated systolic blood pressure, and impaired
glucose metabolism showed higher activin A levels, whereas
no differences in activin A levels were observed for elevated
triglycerides and lower HDL cholesterol phenotypes.
As no validated reference limits for activin A levels exist, a
cut-off level of 325 pg/mL corresponding to the upper limit
value of the 95% conﬁdence interval in healthy non-obese sub-
jects was speciﬁed. In obese subjects, higher activin A levels
(>325 pg/mL) were associated with increasing age,
higher BMI, waist and hip circumference, systolic blood pres-
sure, glucose and fasting insulin levels, and higher MMP-9
levels (Table 2).
Activin A and epicardial fat thickness
Moreover, a gradual increase of EFT could be observed
across increasing tertiles of activin A levels (Figure 1A),
Table 1 Baseline characteristics of the obese study population in comparison with the healthy non-obese control group
BMI range
Non-obese group Obese group
P-value19.0–29.9 30.0–76.0
N 60 236
Age (years) 46.6 ± 12.9 48.3 ± 12.5 0.341
Male [n (%)] 20 (33.3) 95 (40.3) 0.320
BMI (kg/m2) 24.8 ± 3.4 39.8 ± 7.9 <0.001
Waist (cm) 85 ± 10 118 ± 19 <0.001
WHR 0.82 ± 0.07 0.91 ± 0.10 <0.001
HR (beats/min) 68 ± 14 73 ± 13 0.011
SBP (mmHg) 128 ± 16 139 ± 18 <0.001
DBP (mmHg) 80 ± 11 88 ± 12 <0.001
Fasting glucose (mg/dL) 85 ± 8 100 ± 30 <0.001
Fasting insulin (U/mL) 8 ± 5 23 ± 19 <0.001
HOMA-IR 1.7 ± 1.1 6.5 ± 8.1 <0.001
Triglycerides (mg/dL) 105 ± 66 144 ± 81 <0.001
HDL (mg/dL) 85 ± 19 48 ± 14 <0.001
NT-proBNP (ng/L) 58 ± 51 87 ± 233 0.352
Activin A level (pg/mL) 301 ± 94 362 ± 124 <0.001
Adiponectin (μg/mL) 11.4 ± 7.5 8.9 ± 3.9 0.016
MMP-9 level (ng/mL) 503 ± 253 614 ± 331 0.016
BMI, body mass index; DBP, diastolic blood pressure; HDL, high density lipoprotein; HR, heart rate; HOMA-IR, homeostasis model assess-
ment–insulin resistance; MMP-9, matrix metallopeptidase 9; NT-proBNP, N-terminal pro-brain natriuretic peptide; SBP, systolic blood pres-
sure; WHR, waist-to-hip ratio.
Values represent the mean ± standard deviation or numbers (percentages).
Table 2 Comparison of metabolic syndrome parameters, serum markers, and physical performance by dichotomized activin A serum
levels
Activin A level ≤ 325 pg/mLa Activin A level > 325 pg/mLa P-value
N (%) 97 (41.1) 139 (58.9)
Age (years) 42.6 ± 11.2 52.3 ± 11.8 <0.001
Male [n (%)] 36 (37.1) 59 (42.4) 0.413
BMI (kg/m2) 37.6 ± 5.7 41.3 ± 8.8 <0.001
Hip circumference (cm) 126 ± 14 133 ± 19 0.001
Waist circumference (cm) 112 ± 17 122 ± 20 0.001
WHR 0.90 ± 0.11 0.93 ± 0.09 0.026
SBP (mmHg) 136 ± 16 142 ± 18 0.007
DBP (mmHg) 86 ± 11 89 ± 12 0.072
HR (beats/min) 73 ± 13 72 ± 13 0.855
Fasting glucose (mg/dL) 94 ± 31 104 ± 29 0.017
Fasting insulin (U/mL) 18 ± 12 26 ± 22 <0.001
HOMA-IR 4.3 ± 3.8 7.3 ± 9.0 0.001
Triglycerides (mg/dL) 133 ± 68 152 ± 88 0.057
HDL (mg/dL) 49 ± 15 47 ± 13 0.391
NT-proBNP (ng/L) 58 ± 61 105 ± 292 0.192
Adiponectin (μg/mL) 8.7 ± 3.2 9.1 ± 4.4 0.425
MMP-9 (ng/mL) 562 ± 261 677 ± 348 0.005
Abbreviations as in Table 1. Values represent the mean ± standard deviation or numbers (percentages).
aThe activin A cut-off limit of 325 pg/mL corresponds to the upper limit value of the 95% conﬁdence interval of the healthy non-obese
control group.
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and a higher EFT could be observed in subjects with
activin A levels > 325 pg/mL (Figure 1B). This association
remained signiﬁcant after adjusting for age, sex, and BMI
(P = 0.015). Echocardiographic evidence of left ventricular
diastolic dysfunction (LVDD) was strongly associated with
EFT (Figure 1C), and, in turn, subjects with LVDD had
higher activin A levels than subjects with normal LV func-
tion (Figure 1D).
Figure 1 (A) Association of tertiles of activin A serum levels with epicardial fat thickness (EFT). (B) Association of dichotomized activin A levels with EFT.
(C) Association of left ventricular diastolic function with EFT. (D) Association of left ventricular diastolic function with activin A levels.
Figure 2 Association of different obesity groups with low and high epicardial fat thickness (EFT) with activin A serum levels and left ventricular diastolic
dysfunction (LVDD). MetS, metabolic syndrome; OB, obese; low EFT, EFT ≤ 7.4 mm; high EFT, EFT > 7.4 mm (the cut-off corresponds to the 95% con-
ﬁdence interval of all obese study participants in the Regensburg Weight loss study).
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Furthermore, activin A levels increased signiﬁcantly across
the spectrum of obesity (Figure 2): speciﬁcally, non-obese
control subjects followed by obese subjects with low EFT
showed the lowest activin A levels, and MetS obese subjects
with high EFT (>7.4 mm thickness, corresponding to the 95%
conﬁdence interval in the total obese group) showed the
highest activin A levels. The same relationship could be ob-
served with respect to the frequency of LVDD (Figure 2).
Activin A and left ventricular diastolic dysfunction
In Table 3, different echocardiographic measurements of LA
and LV geometry as well as parameters of LV systolic and di-
astolic function are displayed by dichotomized activin A
levels. A signiﬁcant association of elevated activin A levels
with LA size, LV end-diastolic diameter, interventricular and
posterior wall thickness, and LVM as well as E/A, E/e0, and
e0/a0 could be assessed. Moreover, obese participants with
higher activin A levels > 325 pg/mL covered a signiﬁcant
shorter walking distance during the 6 min walk test (Table 3).
Additionally, impaired values of e0, E/e0, E/A + DT, and LA
size were associated with signiﬁcantly elevated activin A
levels (Table 4).
Discussion
In our obese study population (ø BMI 39.8 ± 7.9 kg/m2),
activin A levels were positively associated with most parame-
ters of the MetS, increased with the number of MetS compo-
nents, and were positively correlated with EFT. Moreover,
elevated activin A levels were signiﬁcantly associated with dif-
ferent parameters of LA and ventricular geometry as well as
parameters of diastolic dysfunction. As a gradual increase of
elevated activin A levels across increasing EFT could be ob-
served independently from body mass, we conclude that
Table 3 Comparison of echocardiographic parameters in obese subjects by dichotomized activin A serum levels
Activin A level ≤ 325 pg/mLa Activin A level > 325 pg/mLa P-value
N (%) 97 (41.1) 139 (58.9)
LAA (cm2) 18.3 ± 3.7 20.3 ± 5.0 0.003
LVEDD (mm) 50.8 ± 5.3 52.3 ± 5.4 0.042
LVESD (mm) 32.0 ± 4.4 32.6 ± 5.3 0.337
IVS (mm) 10.6 ± 1.7 11.2 ± 2.0 0.017
PW (mm) 10.1 ± 1.5 10.6 ± 1.6 0.027
LVM (g) 114 ± 26 124 ± 30 0.018
EF (%) 65 ± 7 64 ± 7 0.217
DT (ms) 190 ± 44 215 ± 68 0.001
E/A 1.2 ± 0.4 1.1 ± 0.4 0.035
e0 (cm/s) 13.0 ± 3.9 11.8 ± 4.9 0.058
E/e0 6.6 ± 2.2 7.4 ± 2.5 0.028
e0/a0 1.5 ± 0.7 1.2 ± 0.5 0.001
6MWT (m) 580 ± 68 528 ± 97 <0.001
A, late diastolic mitral inﬂow; e0, early diastolic mitral annular tissue velocity; a0, late (atrial contraction) diastolic mitral annular tissue ve-
locity; DT, deceleration time; E, early diastolic mitral inﬂow; EF, ejection fraction; IVS, interventricular septum thickness; LAA, left atrial
area; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; LVM, left ventricular mass; PW, posterior
wall; 6MWT, 6 min walking test.
Values represent the mean ± standard deviation.
aThe activin A cut-off limit corresponds to the upper limit value of the 95% conﬁdence interval of the healthy non-obese control group.
Table 4 Activin A serum levels compared in normal and pathologic diastolic function parameters
Activin A level (pg/mL) when
diastolic function parameter is normal
according to prespeciﬁed criteria
Activin A level (pg/mL) when
diastolic function parameter is pathologic
according to prespeciﬁed criteria P-value
LVDD 355 ± 125 389 ± 117 0.037
Low e0 353 ± 125 392 ± 117 0.010
High E/e0 356 ± 127 394 ± 108 0.005
Impaired E/A + DT 357 ± 123 4265 ± 112 0.007
Low e0/a0 355 ± 125 397 ± 113 0.009
Increased LA size 352 ± 125 382 ± 117 0.024
Increased LVM 352 ± 116 381 ± 125 0.060
Abbreviations as in Table 3; LA, left atrial; LVDD, left ventricular diastolic dysfunction; LVDD as deﬁned in the methods section according
to the American Society of Echocardiography 2009 and European Society of Cardiology 2007 consensus criteria19,20; e0 was patho-
logic < 10 cm/s; E/e0 was pathologic ≥ 8; E/A ≤ 0.8 + DT > 200 was pathologic; e0/a0 was pathologic ≤ 0.8; LA size (= left atrial size) was
pathologic with LAA (4 chamber planimetry)> 20 cm2 or LA diameter (parasternal long axis)> 48 mm; LVMwas pathologic> 149 g/m2 in
men and >122 g/m2 in women.
Values represent the mean ± standard deviation.
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activin A released from epicardial adipose tissue cells may be
involved in the cardiometabolic dysfunctioning, given the
ﬁndings from experimental animal models, the fact that
activin A is abundantly secreted by human epicardial adipose
tissue of diabetic and obese patients,23 and the consistent re-
sults of human epicardial adipose tissue secretome analysis.7
To the best of our knowledge, this is the ﬁrst clinical study
correlating activin A levels with cardiometabolic disturbances
that may ultimately lead to heart failure.
Epicardial adipose tissue is a source of several inﬂamma-
tory mediators and shares the same microcirculation with
myocardial cells.24 Thus, mediators expressed by epicardial
adipose tissue may directly inﬂuence myocardial function.
Activin A is expressed in many immune cells, such as mono-
cytes, macrophages, dentritic cells, T and B lymphocytes,
and mast cells, and its expression increases by the activation
of various immune stimuli.9
Preceding experimental investigations have suggested that
activin A was associated with the occurrence and severity of
heart failure8,25; however, the underlying mechanisms are
still unclear. Previous experimental studies on the relation-
ship between heart failure and activin A focused on promot-
ing myocardial hypertrophy and ﬁbrosis26,27 and investigated
the role of the activin A–follistatin system in myocardial cell
apoptosis,28,29 whereby follistatin directly binds to activin A,
inhibiting the physiological action of activin A.30 From the lat-
ter studies, it has been suggested that an imbalance of the
activin A–follistatin system in animal models of heart failure
causes up-regulation of activin A and down-regulation of
follistatin, proposing that the activin A–follistatin system is in-
volved in endoplasmic reticulum stress-mediated myocardial
cell apoptosis in heart failure.
However, most available evidence came from experimen-
tal studies suggesting that activin A is an important factor
of inducing myocardial ﬁbrosis.12,31 Speciﬁcally, it has been
shown that overexpression of activin A leads to ventricular
remodelling in rat models of heart failure.12 Moreover, activin
A promoted gene expression of atrial natriuretic peptides and
MMP-9, which are known to be factors playing an important
role in myocardial remodelling and interstitial ﬁbrosis,8 are
associated with severity of chronic heart failure, and have
been identiﬁed to predict heart failure events.32 Recent re-
search has also demonstrated that the secretome from hu-
man epicardial (but not subcutaneous) adipose tissue can
induce myocardial ﬁbrosis and that the adipo-ﬁbrokine
activin A constitutes an important mediator of this pro-
ﬁbrotic effect, which can be neutralized by an anti-activin A
antibody.7 Interestingly, further ﬁndings have suggested that
the angiotensin-converting enzyme inhibitor Ramipril
beneﬁted LV remodelling by reducing ﬁbrosis and collagen
accumulation in the left ventricle of rats after myocardial in-
farction, an observation which was also associated with
down-regulation of activin A expression.33 Besides these ef-
fects, activin A has been described as an additional factor
contributing to diabetic cardiomyopathy.14,23 Activin A re-
leased from epicardial adipose tissue of obese type 2 diabetic
patients provoked impairment of myocardial contractility by
reduction of sarcomer shortening, cytosolic calcium ﬂow
and expression of sarco/endoplasmic reticulum Ca2+ ATPase
and decreased insulin-mediated glucose uptake in atrial rat
cardiomyocytes.23
Our results are consistent with these earlier ﬁndings impli-
cating a relationship between obesity (particularly when
there is evidence of insulin resistance or the MetS is present),
epicardial tissue, activin A, MMP-9 levels, and signs of LVDD.
Taken together, observations from the literature together
with our present clinical data provide compelling evidence
that activin A is an important mediator of the pro-ﬁbrotic ef-
fect of epicardial adipose tissue on human myocardium and
LV structure and function.
Study limitations
Our study has several limitations. First, the way of recruit-
ment of study participants may be lead to selection bias. Sec-
ond, a large variability of echocardiographic parameters,
especially in consequence of limited testing conditions in ex-
tremely obese subjects, could impact our results. However,
concordance for 20 duplicate measurements of two expert
echocardiographers was very high for tissue Doppler mea-
surements. Third, we can present only associations between
activin A, EFT, and diastolic function parameters and not give
evidence of a causal link.
Conclusions
In conclusion, our data conﬁrm the pre-existing investigations
that epicardial adipose tissue in severe obesity leads to en-
hanced release of the inﬂammatory marker activin A, espe-
cially in patients with insulin resistant MetS. In these
patients, activin A may be involved in the pathogenesis
of myocardial ﬁbrosis leading to impaired LV diastolic
function, which represents an early sign of obesity-related
heart disease.
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